The groundbreaking success of Viagra undeniably revolutionized the drug landscape, but betting in companies heavily reliant on off-patent versions presents a challenging picture. While early returns were substantial, the end of patents and the rise of discounted alternatives have weakened the customer base. Therefore, a thorough assessment of prese